Literature DB >> 21713460

Preclinical evaluation of drug in adhesive type ondansetron loaded transdermal therapeutic systems.

Kalpana Swain1, Satyanarayan Pattnaik, Nilufa Yeasmin, Subrata Mallick.   

Abstract

The in vivo assessment of percutaneous absorption of molecules is a very important step in the evaluation of any transdermal drug delivery system and a key goal in the design and optimization of transdermal dosage forms lies in understanding the factors that determine a good in vivo performance. The objective of the present investigation is to assess the in vivo performance of an optimized transdermal system of ondansetron hydrochloride in rabbits and to generate preclinical pharmacokinetic data. The pharmacokinetic performance of ondansetron hydrochloride following intravenous and transdermal administration was studied in rabbits following non compartmental pharmacokinetic analysis. The pharmacokinetic parameters such as area under the curve, elimination rate constant, elimination half life and mean residence time, were significantly (P < 0.01) different following transdermal administration compared to intravenous administration. Absolute bioavailability of the transdermal film studied was estimated to be 0.37 ± 0.06 which is quite low because a very high drug loading in the transdermal system was essential to achieve sufficient thermodynamic activity for transdermal permeation. Though in vivo studies in rabbits are found promising, investigations in healthy human subjects are essential to confirm the performance of the developed transdermal films.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21713460     DOI: 10.1007/s13318-011-0053-x

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  8 in total

1.  Comparison of human skin or epidermis models with human and animal skin in in-vitro percutaneous absorption.

Authors:  F P Schmook; J G Meingassner; A Billich
Journal:  Int J Pharm       Date:  2001-03-14       Impact factor: 5.875

2.  In vitro - in vivo correlation: from theory to applications.

Authors:  Jaber Emami
Journal:  J Pharm Pharm Sci       Date:  2006       Impact factor: 2.327

3.  Drug in adhesive type transdermal matrix systems of ondansetron hydrochloride: optimization of permeation pattern using response surface methodology.

Authors:  Kalpana Swain; Satyanarayan Pattnaik; Sarat Chandra Sahu; Kiran Kumar Patnaik; Subrata Mallick
Journal:  J Drug Target       Date:  2010-02       Impact factor: 5.121

4.  Formulation of a reservoir-type testosterone transdermal delivery system.

Authors:  M K Kim; H Zhao; C H Lee; D D Kim
Journal:  Int J Pharm       Date:  2001-05-21       Impact factor: 5.875

5.  Comparative in vivo evaluation of propranolol hydrochloride after oral and transdermal administration in rabbits.

Authors:  P Rama Rao; M Narender Reddy; Sistla Ramakrishna; Prakash V Diwan
Journal:  Eur J Pharm Biopharm       Date:  2003-07       Impact factor: 5.571

6.  Effect of PEG6000 on the in vitro and in vivo transdermal permeation of ondansetron hydrochloride from EVA1802 membranes.

Authors:  Yellela S R Krishnaiah; Bukka Rama; Vanambattina Raghumurthy; Kolapalli V Ramanamurthy; Vemulapalli Satyanarayana
Journal:  Pharm Dev Technol       Date:  2009       Impact factor: 3.133

7.  Transdermal dual-controlled delivery of contraceptive drugs: formulation development, in vitro and in vivo evaluations, and clinical performance.

Authors:  Y W Chien; T Y Chien; R E Bagdon; Y C Huang; R H Bierman
Journal:  Pharm Res       Date:  1989-12       Impact factor: 4.200

Review 8.  Transdermal skin delivery: predictions for humans from in vivo, ex vivo and animal models.

Authors:  Biana Godin; Elka Touitou
Journal:  Adv Drug Deliv Rev       Date:  2007-08-16       Impact factor: 15.470

  8 in total
  1 in total

1.  Ondansetron HCl Microemulsions for Transdermal Delivery: Formulation and In Vitro Skin Permeation.

Authors:  Jadupati Malakar; Amit Kumar Nayak; Aalok Basu
Journal:  ISRN Pharm       Date:  2012-06-19
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.